Lobbying Information
Subject Matters
- Aboriginal Affairs
- Budget
- Consumer Issues
- Environment
- Government Procurement
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Trade
- Labour
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
Legislative Proposal, Bill or Resolution, Policies or Program
- International Trade policy initiatives related to implementing / strengthening the Canada-Europe Trade Agreement (CETA)and the Trans-Pacific Partnership (TPP), including recognition of patent term restoration within Canada's intellectual property protection regime
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act & regulations as they relate to export restrictions and cross border trade of biopharmaceuticals.
Policies or Program
- Canadian Institutes of Health (CIHR) initiatives, such as the Drug Safety and Effectiveness Network (DSEN), and various research programs, particularly as they relate to public/private research and development partnerships
- Environment and Climate Change Canada and/or Food and Drugs Act regulations as they relate to the safe and environmentally responsible disposal of biopharmaceutical compounds.
- Existing or proposed policies and programs related to ensuring availability and access to effective cancer treatments for Canadian patients.
- Existing or proposed policies and programs related to improving access to effective treatments for common mental health, addiction and neuro-degenerative for Canadian patients.
- Federal Health Partnership with respect to the co-ordination of federal health benefit plan policies and programs.
- Federal policies related to, and interactions with, the Canadian Agency for Drugs and Technologies in Health (CADTH) particularly pertaining to its Common Drug Review (CDR), pan-Canadian Oncology Drug Review (pCODR), Health Technology Assessment (HTA), and the Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) units.
- Federal policies related to, and interactions with, the pan-Canadian Oncology Drug Review (pCODR).
- Health Canada (including the Office of Patented Medicines and Liason (OPML)) policies and regulations with regards to therapeutic products
- Health benefits programs of Immigration, Refugees and Citizenship Canada, Correctional Services of Canada, Health Canada (NIHB), the Department of National Defence, the Royal Canadian Mounted Police, and Veterans Affairs Canada with respect to decisions and policies which impact the reimbursement of biopharmaceutical therapeutic products for plan beneficiaries.
- International Trade Canada's "Invest in Canada" policies and programs with respect to investment, business development and innovation in the life sciences industry sector.
- Mobilizing Science and Technology to Canada's Advantage, the federal science and technology strategy, with respect to the health and related life sciences and technologies priority area
- Modernization of Health Canada's Progressive Licensing framework as it relates to the review and approval of biopharmaceutical products
- National Pharmaceutical Strategy (NPS) as it relates to the federal government's involvement in the federal/provincial/territorial governments' access to medicines framework
- Pan-Canadian Pricing Alliance as it relates to drug pricing and reimbursement.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program as it relates to investment in biopharmaceutical and related health technology innovation.
Policies or Program, Regulation
- Data exclusivity as it relates to the use of Natural Health Products in biopharmaceutical preparations.
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
Regulation
- Food and Drug Regulations as it relates to data protection (Section C.08.004) and the regulation and protection of biopharmaceutical products
- Patent Act with respect to Patented Medecines (Notice of Compliance (NOC)) Regulations
- Patented Medicines Prices Review Board (PMPRB) Regulations as they relate to reporting requirements and pricing guidelines as well as reference pricing and the modernization of PMPRB regulatory framework.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canada Economic Development for Quebec Regions
-
Canada Foundation for Innovation
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Competition Bureau Canada (COBU)
-
Correctional Service of Canada (CSC)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Immigration, Refugees and Citizenship Canada (IRCC)
-
Indigenous and Northern Affairs Canada
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
NAFTA Secretariat
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Public Health Agency of Canada (PHAC)
-
Royal Canadian Mounted Police (RCMP)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Lundbeck Canada develops, manufactures and/or sells innovative biopharmaceutical products for the treatment of disorders originating in the central nervous system (CNS) and for the treatment of cancer.
Responsible officer name and position during the period of this registration
Sylvie Pilon,
Vice President & General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
2600 Alfred Nobel Boulevard
Suite 400
Ville Saint-Laurent, QC H4S 0A9
Canada
Telephone number:
514-844-8515
Parent Company Information
- H. Lundbeck a/s
-
Ottilavej 9
Copenhagen Valby DK-2500
Denmark
Subsidiary Beneficiary Information
Lundbeck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Nadine Abdalla,
Senior Reimbursement Strategy Manager |
No public offices held
- Joanna Bougie,
Scientific Advisor |
No public offices held
- Gina Cameron,
Regional Business Manager |
No public offices held
- Marcel Chénard,
Senior Director, Oncology Business Unit |
No public offices held
- Ann Julie Comeau,
CHE Manager |
No public offices held
- Nina Courchesne,
Senior Manager, Medical Information |
No public offices held
- Veronique Dahan,
Senior Project Manager, Regulatory Affairs |
No public offices held
- Elizabeth Dunton,
Senior Manager, Market Access |
No public offices held
- Wissam El-Hadi,
Senior Reimbursement Strategy Manager |
No public offices held
- Diane Guilbault,
Senior Manager, Quality Assurance |
No public offices held
- Judith Haimovici,
Senior Product Manager |
No public offices held
- Stéphane Jean,
Specialist, Medical Information |
No public offices held
- Marie-Pier Ladouceur,
Specialist, Market Access |
No public offices held
- Michael Leo,
Senior Manager, Market Access |
No public offices held
- Erin Mackenzie,
Scientific Advisor |
No public offices held
- Daniel McCarthy,
Senior Director, Market Access |
No public offices held
- Takuhi Mirasyedi,
Senior Manager, Regulatory Affairs |
No public offices held
- Sylvie Pilon,
Vice President & General Manager |
No public offices held
- Jean Proulx,
Senior Director, Medical & Regulatory Affairs |
No public offices held
- Chantal Venne,
Specialist, Quality Assurance |
No public offices held
- My-Anh Wioland,
Specialist, Quality Assurance |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
No lobbyists added
